Introduction
Primary pleural non-Hodgkin lymphoma (PPL) represents an exceptionally uncommon extranodal lymphoid malignancy, accounting for less than 0.3% of all non-Hodgkin lymphoma (NHL) presentations (1,2,3). Unlike secondary pleural involvement from disseminated systemic lymphoma, PPL originates primarily within the pleural tissue without widespread lymphadenopathy or extrathoracic organ disease. In tuberculosis-endemic geographical regions, young patients presenting with exudative pleural effusions and pleural thickening are frequently misdiagnosed with pleural tuberculosis or malignant mesothelioma, leading to empirical anti-tubercular therapy and prolonged diagnostic delays (3).
Furthermore, the management of rare thoracic malignancies is fraught with potential treatment-related toxicities. Although chemo-immunotherapy with rituximab-based regimens (such as R-CHOP) has dramatically improved progression-free survival in CD20-positive B-cell lymphomas, rituximab-induced interstitial lung disease (R-ILD) occurs in 3.7% to 10% of treated patients (4,5). When compounded by cancer-associated venous thromboembolism (VTE) and acute pulmonary embolism (PE), these overlapping pulmonary insults create a life-threatening clinical state that poses severe diagnostic and therapeutic challenges.
Herein, we report a rare case of PPL in a 27-year-old male that presented as a hemorrhagic, low-adenosine deaminase (ADA) exudative effusion with pleural nodularity, successfully diagnosed via immunohistochemistry and PET-CT, but complicated by fatal concurrent rituximab-induced pneumonitis and pulmonary thromboembolism.
Case presentation
A 27-year-old male garment shop owner presented to the respiratory medicine outpatient department of a tertiary care university hospital in Northeast India with a 2-week history of left-sided pleuritic chest pain, progressive breathlessness, dry cough, and loss of appetite. He was a non-smoker with no prior chronic medical illness, but reported close household contact with his sister who had been diagnosed with tubercular lymphadenitis 1 month prior. Physical examination revealed a thin-built male with stable vital signs (blood pressure 120/74 mmHg, pulse rate 86 beats/min, respiratory rate 20 breaths/min, and oxygen saturation 96% on room air). Chest percussion demonstrated a stony dull note over the left infrascapular and infra-axillary zones, accompanied by significantly diminished breath sounds.
Chest radiography (PA view) showed a left-sided sub-massive pleural effusion with contralateral tracheal displacement (Figure 1). Diagnostic thoracentesis yielded gross hemorrhagic pleural fluid. Pleural fluid biochemistry and cell analysis revealed an exudative effusion by Light’s criteria, with a total protein 5.2 g/dL (paired serum protein: 6.9g/dl, ratio 0.75), lactate dehydrogenase (LDH) 1580 U/L (paired serum LDH: 290U/L; ratio 5.45, upper limit of normal for serum LDH: 220 U/L), glucose 79 mg/dL, albumin 3.2 g/dL, and total nucleated cell count 300 cells/cu.mm (82% lymphocytes, 18% polymorphs) with abundant red blood cells (Table 1).
| Parameter | Initial Presentation | ICU Readmission (2 Months Post-R-CHOP) | Units |
|---|---|---|---|
| Pleural Fluid Protein | 5.2 | Not applicable | g/dL |
| Pleural Fluid LDH | 1580 | Not applicable | U/L |
| Pleural Fluid Glucose | 79 | Not applicable | mg/dL |
| Pleural Fluid ADA | 18 | Not applicable | IU/L |
| Pleural Fluid Cell Count | 300 | Not applicable | cells/cu.mm |
| Hemoglobin | 11.3 | 10.8 | g/dL |
| Total Leukocyte Count (TLC) | 10100 | 11400 | cells/cu.mm |
| Platelet Count | 238000 | 215000 | cells/cu.mm |
| Serum NT-proBNP | Not measured | 63 | pg/mL |
Adenosine deaminase (ADA) was low at 18 IU/L (reference cut-off >40 IU/L for tuberculosis(6)). Pleural fluid acid-fast bacilli (AFB) smear, cartridge-based nucleic acid amplification test (CBNAAT/GeneXpert) for Mycobacterium tuberculosis, and fluid cytology for malignant cells were all negative. Complete blood count showed hemoglobin 11.3 g/dL, total leukocyte count 10,100 cells/cu.mm (78% neutrophils, 17% lymphocytes, 3% eosinophils, 2% monocytes), and platelet count 238,000 cells/cu.mm. Serological testing for HIV, Hepatitis B, and Hepatitis C was negative. A 24F intercostal drainage (ICD) tube was placed in the 4th intercostal space within the triangle of safety to relieve dyspnea, and fluid was sent for cell block preparation.
Contrast-enhanced computed tomography (CECT) of the thorax revealed irregular, nodular enhancing thickening along the left costal and diaphragmatic pleura associated with left pleural effusion and sub-centimetric mediastinal lymph nodes, highly suspicious for a primary pleural neoplasm (? mesothelioma). Thoracic ultrasound (TUS) confirmed multiple lobulated, hypoechoic pleural mass lesions (Figure 2). Ultrasound-guided transthoracic fine-needle aspiration cytology (FNAC) and cell block cytology were performed.
Diagnostic cytology revealed a striking morphological discordance. Cell block cytology demonstrated monomorphic tumor cells arranged in sheets with irregular nuclear membranes, vesicular chromatin, and scanty cytoplasm, favouring non-Hodgkin lymphoma with a differential diagnosis of small-cell lung carcinoma (Figure 3).
Conversely, FNAC smears showed non-cohesive hyperchromatic nuclear sheets without visible cytoplasm or nucleoli, favouring small-cell lung carcinoma over hematolymphoid malignancy (Figure 4).
To resolve this conflict, immunohistochemical (IHC) panel testing was conducted. The tumor cells showed strong, diffuse membranous positivity for leukocyte common antigen (CD45) and B-cell marker CD20, while T-cell marker CD3 and epithelial marker cytokeratin AE1/AE3 were negative (Figure 5), indicating diagnosis of B-cell Non-Hodgkin Lymphoma. As FNAC and cell block sample adequately established the diagnosis, and patient didn’t give consent to undergo any more invasive procedure, core needle biopsy even though planned, could not be performed.
Whole-body 18F-fluorodeoxyglucose (FDG) PET-CT scan demonstrated a large, intensely FDG-avid heterogeneous enhancing pleural-based mass (6.3 × 10.9 cm, SUVmax 7.1) in the left basal region abutting the diaphragm. Sub-centimetric highest mediastinal, upper paratracheal, subcarinal, and hilar lymph nodes exhibited non-to-faint FDG uptake, reported as reactive lymphadenopathy (Figure 6).With no extrathoracic lymphadenopathy or organ involvement, a diagnosis of Primary Pleural B-cell Non-Hodgkin Lymphoma was confirmed. The patient was initiated on chemo-immunotherapy with the R-CHOP regimen (rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², and oral prednisolone 100 mg daily for 5 days), scheduled on a standard 21 day cycle.
Two months after completing two cycles of R-CHOP, the patient presented again to the emergency department with rapidly progressive breathlessness and dry cough. Physical examination revealed bilateral lung crackles and severe hypoxemia (SpO2 90% on 10 L/min oxygen via non-rebreather mask). Chest radiograph demonstrated bilateral reticular opacities. He was transferred to the intensive care unit (ICU) and intubated. Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) level was normal (63 pg/mL), ruling out doxorubicin-induced cardiomyopathy. Urgent CT pulmonary angiography (CTPA) revealed a filling defect in the left main pulmonary artery extending into lobar and segmental arteries, confirming acute pulmonary thromboembolism. Concurrently, lung window images demonstrated extensive ground-glass opacities (GGOs) with interlobular septal thickening in the right lung parenchyma, alongside residual left pleural mass (8.5 × 3.25 × 10.04 cm) (Fig. 7), establishing dual complications of rituximab-induced interstitial lung disease (R-ILD) and acute pulmonary embolism. High-dose intravenous methylprednisolone (1 g/day) was initiated for R-ILD and Low Molecular Weight Heparin (LMWH, 1 mg/kg twice daily) for PE. Systemic thrombolysis was planned for PE, however, despite full ICU support, the patient's oxygenation deteriorated, and he died on the 8th day of admission.
Discussion
Primary pleural non-Hodgkin lymphoma is an exceedingly rare disease entity, accounting for <0.3% of all non-Hodgkin lymphomas (NHLs) (1,3). PPL typically occurs in the setting of long-standing chronic pyothorax (pyothorax-associated lymphoma) or severe immunocompromise such as HIV infection (7,8). Its presentation in a young, immunocompetent individual without preceding empyema or asbestos exposure is exceptionally rare (4). In tuberculosis-endemic countries, young patients with lymphocytic exudative effusions are frequently placed on empirical anti-tubercular therapy. However, pleural fluid ADA levels <40 IU/L while alone don’t definitively exclude pleural tuberculosis with absolute certainty negative pleural fluid AFB smears and negative CBNAAT argued against tuberculosis (6), mandating immediate image-guided tissue biopsy to avoid therapeutic misdirection.
Standard cytological examination of pleural fluid is notoriously non-diagnostic in PPL, yielding positive results in fewer than 25% of cases (4). In our patient, initial FNAC and cell block preparations yielded discordant impressions between small-cell carcinoma and non-Hodgkin lymphoma. Immunohistochemistry proved crucial in establishing lineage: positivity for CD45 and CD20 confirmed B-cell lymphoma, while negativity for cytokeratin AE1/AE3 and CD3 ruled out epithelial carcinoma and T-cell malignancy(5). Furthermore, PET-CT staging was essential to confirm the primary pleural origin, demonstrating high FDG avidity isolated to the pleura (SUVmax 7.1) with non-avid reactive mediastinal nodes and no distant metastases (7).
A critical educational aspect of this case is the development of dual, fatal treatment-related toxicities. Rituximab-induced ILD is a well-documented but under-recognized pulmonary toxicity, typically manifesting 1 to 3 months after chemo-immunotherapy initiation due to massive B-cell lysis and secondary cytokine release (TNF-alpha, IL-6, interferon-gamma) (9,10). Radiologically, R-ILD presents with ground-glass opacities and interlobular septal thickening (11). Simultaneously, active malignancies induce a prothrombotic state through tumor-derived tissue factor expression and procoagulant cytokine release, predisposing patients to venous thromboembolism (12,13). The concurrent occurrence of diffuse parenchymal lung injury and acute central pulmonary artery thrombosis produces profound, synergistic ventilation-perfusion mismatch that is frequently refractory to combined corticosteroid and anticoagulant therapy.
Primary pleural lymphoma (PPL) predominantly affects older adults in their 6th to 8th decades or immunocompromised individuals with chronic pyothorax or HIV infection (4). Its occurrence in young, immunocompetent individuals is exceptionally rare (4). A review of previously reported cases of primary pleural lymphoma in immunocompetent young patients showed marked heterogeneity. Comparison of age, histology, presentation, treatment and outcome of previously reported cases is presented in Table 2.
| Author | Age/Gender | Histological subtype | Presentation | Treatment | Outcome |
|---|---|---|---|---|---|
| Karadeniz et al. (14) | 2.5 years/ Female | T-cell Lymphoblastic Lymphoma | Fever, Severe dyspnea, Massive pleural effusion | Modified LSA2-L2 protocol + Cranial Radiotherapy | Initial complete remission; isolated CNS relapse at 11 months; died of neutropenic sepsis |
| Ravikumar et al. (15) | 12 years/ Female | DLBCL | Fever, nonproductive cough, pleural effusion, pleural peel | Surgical decortication + 6 cycles of MCP 842 chemotherapy | Remission for 13 months; terminal local relapse with respiratory failure |
| Elsayed et al. (16) | 34 years/ Male | Plasmablastic Lymphoma | Pleural effusion with pleural thickening | CHOP chemotherapy | Deceased |
| Steiropoulos et al. (17) | 37 years/ Female | Classical Nodular Sclerosis Hodgkin Lymphoma | Exertional dyspnea, pleural effusion | Systemic chemotherapy (regimen not mentioned) | Complete clinical regression of effusion and long term remission |
Conclusion
Primary pleural lymphoma should be included in the differential diagnosis even in young patients presenting with hemorrhagic exudative pleural effusions, low pleural fluid ADA, and pleural nodularity in tuberculosis-endemic settings. Early image-guided biopsy with immunohistochemistry (CD45/CD20) is essential for diagnostic resolution. Furthermore, clinicians must maintain high vigilance for treatment-related toxicities during rituximab-based chemo-immunotherapy, as concurrent rituximab-induced ILD and pulmonary thromboembolism carry an extremely high risk of rapid clinical deterioration and death.
Author contribution
SB and TCS contributed to the conceptualization of the case report. SB and TT contributed to data curation and investigation. SB, TCS, and SH contributed to the formal analysis and methodology. SB and TT wrote the initial manuscript. TCS and SH contributed to critical review and editing of the manuscript. SH and SB provided supervision and project administration. All authors reviewed and approved the final version of the manuscript.
Conflicts of interest
There are no conflicts of interest.
Funding
There is no funding.
References
- Sapkota S, Shaikh H. Non-Hodgkin lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
- Aozasa K, Tsujimoto M, Sakurai M, et al. Non-Hodgkin's lymphomas in Osaka, Japan. Eur J Cancer Clin Oncol. 1985;21(4):487–492.
- Yang X, Xu X, Song B, et al. Misdiagnosis of primary pleural DLBCL as tuberculosis: a case report and literature review. Mol Clin Oncol. 2018;8(6):729–732.
- Paredes CS, Lauretta J, Semprun M, et al. Primary pleural lymphoma in an immune-competent patient: a diagnostic and therapeutic challenge. J Pers Med. 2025;15(5):162.
- Sethi A, Tandon A, Mishra H, et al. Diffuse large B-cell lymphoma: an immunohistochemical approach to diagnosis. J Oral Maxillofac Pathol. 2019;23(2):284–288.
- Lee J, Park J, Lim JK, Park JE, Lee YH, Choi SH, et al. Tuberculous and malignant pleural effusions with adenosine deaminase levels of 40–70 IU/L: trends in new cases over time and differentiation between groups. J Korean Med Sci. 2025;40(13):e35.
- Wang X. PET/CT: appropriate application in lymphoma. Chin Clin Oncol. 2015;4(1):4.
- Iuchi K, Ichimiya A, Akashi A, et al. Non-Hodgkin's lymphoma of the pleural cavity developing from long-standing pyothorax. Cancer. 1987;60(8):1771–1775.
- Chari R, Abdelghany Y, Purcell M, et al. Rituximab induced lung injury. BMC Pulm Med. 2025;25(1):359.
- Spagnolo P, Bonniaud P, Rossi G, et al. Drug-induced interstitial lung disease. Eur Respir J. 2022;60(5):2102776.
- Lioté H, Lioté F, Séroussi B, et al. Rituximab-induced lung disease: a systematic literature review. Eur Respir J. 2010;35(3):681–687.
- Park DY, An S, Kashoor I, et al. In-hospital prognosis of malignancy-related pulmonary embolism: an analysis of the national inpatient sample 2016–2018. J Thromb Thrombolysis. 2022;54(3):630–638.
- Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490–5505.
- Karadeniz C, Güven MA, Ruacan Ş, Demirbilek S, Sağbil Ş, Akhan O. Primary pleural lymphoma: an unusual presentation of childhood non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2000;17(8):695–699.
- Ravikumar G, Tirumalae R, Das K. Primary pleural non-Hodgkin lymphoma in a child—an exceedingly rare disease. J Pediatr Surg. 2012;47(6):E29–E31.
- Elsayed M, Ali A, Andrijevskiene G. Plasmablastic lymphoma manifesting as pleural thickening and effusion: a case report. Cureus. 2024;16(11):e73961.
- Steiropoulos P, Kouliatsis G, Karpathiou G, Popidou M, Froudarakis ME. Rare cases of primary pleural Hodgkin and non-Hodgkin lymphomas. Respiration. 2009;77(4):459–463.